Study of HER2 Mutations and Treatment in Advanced Non-Small Cell Lung Cancer Patients in Italy The HEROS Observational and Prospective Multi-Center Study

What this Trial Is About

Researchers are conducting the HEROS study, a multi-center observational and prospective study in Italy, to investigate the current diagnostic and treatment approaches for HER2-mutated advanced non-small cell lung cancer NSCLC. This study works with the ATLAS project, which collects data from over 59 centers on newly diagnosed advanced NSCLC patients, to understand how common HER2 mutations are and how they are managed in routine clinical practice. Patients enrolled in the ATLAS project from September 2024 to September 2025 will be included to study the prevalence of HER2 mutations. Approximately 100 patients with HER2 mutations will be closely observed for secondary and exploratory objectives. Additionally, a subset of 25 centers will collect blood and tissue samples from available tumor sites to perform biomarker analyses, further exploring the biological characteristics of these cancers. Participants will be followed for 12 months after enrollment to track clinical information and outcomes. Data will be gathered from medical records and biomarker samples when available. The main measure of interest is the prevalence of HER2 mutations over one year. This observational study does not involve any investigational treatments, and participants will continue their usual care while contributing data to help improve understanding of HER2-mutated NSCLC.

Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC